Bivalirudin in Venovenous Extracorporeal Membrane Oxygenation: Moving Forward in the Real World
- PMID: 34135281
- DOI: 10.1097/CCM.0000000000004964
Bivalirudin in Venovenous Extracorporeal Membrane Oxygenation: Moving Forward in the Real World
Conflict of interest statement
Dr. Nichols disclosed the off-label product use of bivalirudin in heparin-induced thrombocytopenia and in extracorporeal membrane oxygenation circuit anticoagulation. Drs. Caridi-Scheible and Gallagher have disclosed that they do not have any potential conflicts of interest.
Comment on
-
Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin.Crit Care Med. 2021 Jul 1;49(7):1129-1136. doi: 10.1097/CCM.0000000000004944. Crit Care Med. 2021. PMID: 33711003
References
-
- Rivosecchi RM, Arakelians AR, Ryan J, et al. Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Crit Care Med. 2021; 49:1129–1136
-
- Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: A review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013; 1:83–97
-
- Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011; 72:581–592
-
- Bussey H, Francis J; Heparin Consensus Group. Heparin overview and issues. Pharmacotherapy. 2004; 24:103S–107S
-
- The Extracorporeal Life Support Organization. ELSO Anticoagulation Guidelines. 2014. Available at https://www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-2014-... . Accessed January 21, 2021
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
